Amyotrophic lateral sclerosis is a neurodegenerative disease characterised by selective degeneration of motor neurons. This process results in deterioration of muscle strength in the limbs and bulbar ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.